Newland Pharmaceutical Co., Ltd. Class A

Newland Pharmaceutical Co., Ltd. Class A

SSZSE:301277
8.52
CNY
-0.04
(-0.47%)
0.23EPS
44.13P/E
4.11BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A carries a market capitalization of 4.11B, placing it among publicly traded companies globally. Its enterprise value stands at 3.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.11B
Enterprise Value3.44B

Share Statistics

As of September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A has 392.08M shares outstanding.

Shares Outstanding392.08M

Valuation Ratios

As of September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 44.13. The price-to-sales ratio is 5.59, and the price-to-book ratio stands at 2.67.

PE Ratio44.13
PS Ratio5.59
PB Ratio2.67
P/TBV Ratio2.76

Enterprise Valuation

As of September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 33.34 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.34 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.44B versus a market cap of 4.11B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.69
EV / EBITDA33.34
EV / EBIT33.34

Financial Position

As of September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A maintains a current ratio of 6.93, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.24, indicating conservative leverage, while an interest coverage ratio of 814.13 demonstrates strong ability to service its debt obligations.

Current Ratio6.93
Quick Ratio4.37
Debt / Equity0.24
Debt / EBITDA0.04
Interest Coverage814.13

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 6.11, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.07 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.29, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.20, useful for judging operating efficiency across full business cycles. The company generates approximately 747,934.24 in revenue per employee across its workforce of 981.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.66 indicates how many times Newland Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.11
Return on Assets (ROA)5.29
Return on Invested Capital (ROIC)6.07
Return on Capital Employed (ROCE)6.20
Revenue Per Employee747,934.24
Employee Count981.00
Inventory Turnover6.66

Taxes

CNY

Over the twelve months ended September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A recorded 10.77M in income tax expense. That works out to an effective tax rate of 10.53, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 102.22M, leaving 93.01M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax10.77M
Effective Tax Rate10.53

Stock Price Statistics

CNY

As of the close on November 17, 2026, Newland Pharmaceutical Co., Ltd. Class A's stock has declined approximately 35.94% over the past 52 weeks. The 50-day moving average sits at 9.71, while the 200-day moving average is 10.73.

52-Week Price Change-35.94%
50-Day Moving Average9.71
200-Day Moving Average10.73

Income Statement

CNY

Over the twelve months ended September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A generated 733.72M in revenue and converted that into 93.01M in net income, yielding earnings per share of 0.23. EBITDA reached 103.30M, while operating income came in at 116.72M.

Revenue733.72M
Gross Profit210.21M
Operating Income116.72M
Pretax Income102.22M
Net Income93.01M
EBITDA103.30M
EBIT103.30M
Earnings Per Share (EPS)0.23

Balance Sheet

CNY

As of September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A holds 663.35M in cash and equivalents against 3.73M in total debt, resulting in a net debt position of -192.86M. Total book value stands at 1.54B, with working capital of 899.80M providing operational flexibility.

Cash & Cash Equivalents663.35M
Total Debt3.73M
Net Debt-192.86M
Equity (Book Value)1.54B
Book Value Per Share3.92
Working Capital899.80M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-36.76M

Margins

Over the twelve months ended September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A posted a gross margin of 28.65, reflecting its pricing power and cost economics. The operating margin of 15.91 and net profit margin of 12.68 provide insight into operational efficiency.

Gross Margin28.65
Operating Margin15.91
Pretax Margin13.93
Profit Margin12.68
EBITDA Margin14.08

Stock Splits

Newland Pharmaceutical Co., Ltd. Class A's most recent stock split took place on April 16, 2025 with a 5:7 split ratio.

Last Split Date4/16/2025
Split Ratio5:7

Scores

As of September 30, 2026, Newland Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 13.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score13.29